Last reviewed · How we verify
NCT06272305: TREC
TREC - Evaluation of the Impact of Eversion Technical Features on the Rate of Carotid Restenosis
trial testing This research does not require any specific investigation and does not imply any modification of treatment. in Hyperplasia in 500 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | University Hospital, Angers |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 March 2024 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2024 |
Drugs / interventions tested
- This research does not require any specific investigation and does not imply any modification of treatment.
Conditions studied
- Hyperplasia — all drugs for Hyperplasia →
Sponsor
University Hospital, Angers
Who can join
18 and older, any sex, with Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Restenosis due to myo-intimal hyperplasia remains a concern after carotid endarterectomy. It occurs in around 6% of cases. Several risk factors for restenosis have already been identified, such as smoking, hypertension, female gender, diabetes, dyslipidemia and small carotid diameter. The main objective of this prospective multicenter study was to determine whether the technical characteristics of the eversion technique have an influence on the rate of restenosis at 1 year. Between September 2021 and November 2022, we followed all patients undergoing carotid endarterectomy by eversion in 8 French hospitals. Demographic data, operative indications and technical characteristics of the endarterectomies performed were collected. These were defined by the circumferential nature of the carotid bulb according to 3 types (TREC A, B or C), and the length and depth of the endarterectomy according to anatomopathological reports. Post-operative complications were collected as much as doppler ultrasonography at three months and 1 year to quantify restenosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06272305
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperplasia
Currently open trials in the same condition.
- NCT02581137 — Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion · Phase 2 · active not recruiting
Other University Hospital, Angers trials
Trials by the same sponsor.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07470294 — Effectiveness of Different Surgical Techniques for Curative Treatment of Pilonidal Sinus Disease in the Pediatric Popula · not yet recruiting
- NCT07409597 — Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease · NA · not yet recruiting
- NCT07468565 — Surgical Approach for the Treatment of Hirschsprung Disease Using the Swenson Technique (SMILES) · not yet recruiting
- NCT07452952 — Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distre · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06272305 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Angers
- Last refreshed: 22 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06272305.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing